Hepatocyte growth factor stimulated angiogenesis without inflammation: Differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor

Vascular Pharmacology

Volumn 57, Issue 1, 2012, Pages 3-9

  Kaga, Toshihiro ^a   Kawano, Hirokazu ^a   Sakaguchi, Makoto ^a   Nakazawa, Takahiro ^a   Taniyama, Yoshiaki ^b   Morishita, Ryuichi ^b  

^a AnGes MG Inc   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; BFGF; HGF; Inflammation; VGEF

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL; BLOOD VESSEL PERMEABILITY; CELL GROWTH; CELL PROLIFERATION; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; GENE EXPRESSION; GRANULATION TISSUE; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TISSUE PERFUSION; VASCULITIS;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HEPATOCYTE GROWTH FACTOR; INFLAMMATION; INTERLEUKIN-8; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860480089     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.02.002     Document Type: Article

References (24)

1. Akahoshi T., Endo H., Kondo H., Kashiwazaki S., Kasahara T., Mukaida N., Harada A., Matsushima K. Essential involvement of interleukin-8 in neutrophil recruitment in rabbits with acute experimental arthritis induced by lipopolysaccharide and interleukin-1. Lymphokine Cytokine Res. 1994, 13:113-116.
2. Baumgartner I., Pieczek A., Manor O., Blair R., Kearney M., Walsh K., Isner J.M. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123.
3. Baumgartner I., Rauh G., Pieczek A., Wuensch D., Magner M., Kearney M., Schainfeld R., Isner J.M. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann. Intern. Med. 2000, 132:880-884.
4. Belch J., Hiatt W.R., Baumgartner I., Driver I.V., Nikol S., Norgren L., Van Belle E. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011, 377:1929-1937.
5. Chen L.F., Greene W.C. Shaping the nuclear action of NF-kappaB. Nat. Rev. Mol. Cell Biol. 2004, 5:392-401.
6. Chung B.H., Lee J.J., Kim J.D., Jeoung D., Lee H., Choe J., Ha K.S., Kwon Y.G., Kim Y.M. Angiogenic activity of sesamin through the activation of multiple signal pathways. Biochem. Biophys. Res. Commun. 2010, 391:254-260.
7. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
8. Distler J.H., Hirth A., Kurowska-Stolarska M., Gay R.E., Gay S., Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q. J. Nucl. Med. 2003, 47:149-161.
9. Dormandy J., Verstraete M., Andreani D., et al. Second European consensus document on chronic critical leg ischemia. Circulation 1991, 84(Suppl. 4):IV1-26.
10. Gilroy D.W., Lawrence T., Perretti M., Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 2004, 3:401-416.
11. Gong R. Multi-target anti-inflammatory action of hepatocyte growth factor. Curr. Opin. Investig. Drugs 2008, 9:1163-1170.
12. Morishita R., Nakamura S., Hayashi S., Taniyama Y., Moriguchi A., Nagano T., Taiji M., Noguchi H., Takeshita S., Matsumoto K., Nakamura T., Higaki J., Ogihara T. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999, 33:1379-1384.
13. Morishita R., Aoki M., Hashiya N., Makino H., Yamasaki K., Azuma J., Sawa Y., Matsuda H., Kaneda Y., Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004, 44:203-209.
14. Nakajima T., Kitajima I., Shin H., Takasaki I., Shigeta K., Abeyama K., Yamashita Y., Tokioka T., Soejima Y., Maruyama I. Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem. Biophys. Res. Commun. 1994, 204:950-958.
15. Nakamura T., Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2010, 86:588-610.
16. Nikol S., Baumgartner I., Van Belle E., Diehm C., Visoná A., Capogrossi M.C., Ferreira-Maldent N., Gallino A., Wyatt M.G., Wijesinghe L.D., Fusari M., Stephan D., Emmerich J., Pompilio G., Vermassen F., Pham E., Grek V., Coleman M., Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 2008, 17:914-921.
17. Okumura M., Okuda T., Okamoto T., Nakamura T., Yajima M. Enhanced angiogenesis and granulation tissue formation by basic fibroblast growth factor in healing-impaired animals. Arzneimittelforschung 1996, 46:1021-1026.
18. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6853-6866.
19. Powell R.J., Simons M., Mendelsohn F.O., Daniel G., Henry T.D., Koga M., Morishita R., Annex B.H. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008, 118:58-65.
20. Saadoun S., Papadopoulos M.C., Hara-Chikuma M., Verkman A.S. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature 2005, 434:786-792.
21. Sanada F., Taniyama Y., Azuma J., Iekushi K., Dosaka N., Yokoi T., Koibuchi N., Kusunoki H., Aizawa Y., Morishita R. Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence. Hypertension 2009, 53:77-82.
22. Sanada F., Taniyama Y., Iekushi K., Azuma J., Okayama K., Kusunoki H., Koibuchi N., Doi T., Aizawa Y., Morishita R. Negative action of hepatocyte growth factor/c-Met system on angiotensin II signaling via ligand-dependent epithelial growth factor receptor degradation mechanism in vascular smooth muscle cells. Circ. Res. 2009, 105:667-675.
23. Shigematsu H., Yasuda K., Iwai T., Sasajima T., Ishimaru S., Ohashi Y., Yamaguchi T., Ogihara T., Morishita R. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010, 17:1152-1161.
24. Sulpice E., Ding S., Muscatelli-Groux B., Bergé M., Han Z.C., Plouet J., Tobelem G., Merkulova-Rainon T. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell 2009, 101:525-539.